Targeted anti-IL-13 therapies in asthma: current data and future perspectives

References

• Mitchell PD, El-Gammal AI, O’Byrne PM. Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma. Clin Pharmacol Ther. 2016;99:38–48.
   PubMed Web of Science ®Google Scholar
• Rael EL, Lockey RF. Interleukin-13 signaling and its role in asthma. World Allergy Organ J. 2011;4:54–64.
   PubMedGoogle Scholar
• Yang G, Volk A, Petley T, et al. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine. 2004;28:224–232.
   PubMed Web of Science ®Google Scholar
• Kumar RK, Herbert C, Webb DC, et al. Effects of anticytokine therapy in a mouse model of chronic asthma. Am J Respir Crit Care Med. 2004;170:1043–1048.
   PubMed Web of Science ®Google Scholar
• Ma Y, Halayko AJ, Basu S, et al. Sustained suppression of IL-13 by a vaccine attenuates airway inflammation and remodeling in mice. Am J Respir Cell Mol Biol. 2013;48:540–549.
   PubMed Web of Science ®Google Scholar
• Hodsman P, Ashman C, Cahn A, et al. A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics. Br J Clin Pharmacol. 2013;75:118–128.
   PubMed Web of Science ®Google Scholar
• De Boever EH, Ashman C, Cahn AP, et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol. 2014;133:989–996.
   PubMed Web of Science ®Google Scholar
• Corren J. Role of interleukin-13 in asthma. Curr Allergy Asthma Rep. 2013;13:415–420.
   PubMed Web of Science ®Google Scholar
• Hoeck J, Woisetschlδger M. Activation of eotaxin-3/CCLl26 gene expression in human dermal fibroblasts is mediated by STAT6. J Immunol. 2001 15;167:3216–3222.
   PubMed Web of Science ®Google Scholar
• Matsukura S, Stellato C, Georas SN, et al. Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism. Am J Respir Cell Mol Biol. 2001;24:755–761.
   PubMed Web of Science ®Google Scholar
• Neilsen CV, Bryce PJ. Interleukin-13 directly promotes oesophagus production of CCL11 and CCL24 and the migration of eosinophils. ClinExp Allergy. 2010;40:427–434.
   Google Scholar
• Skowron-Zwarg M, Boland S, Caruso N, et al. Interleukin-13 interferes with CFTR and AQP5 expression and localization during human airway epithelial cell differentiation. Exp Cell Res. 2007;313:2695–2702.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest. 1999;103:779–788.
   PubMed Web of Science ®Google Scholar
• Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science. 1998 18;282:2258–2261.
   PubMed Web of Science ®Google Scholar
• Kuperman DA, Huang X, Koth LL, et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med. 2002;8:885–889.
   PubMed Web of Science ®Google Scholar
• Kinyanjui MW, Shan J, Nakada EM, et al. Dosedependent effects of IL-17 on IL-13-induced airway inflammatory responses and airway hyperresponsiveness. J Immunol. 2013 15;190:3859–3868.
   PubMed Web of Science ®Google Scholar
• Saito A, Okazaki H, Sugawara I, et al. Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro. Int Arch Allergy Immunol. 2003;132:168–176.
   PubMed Web of Science ®Google Scholar
• Berry MA, Parker D, Neale N, et al. Sputum and bronchial submucosal IL13 expression in asthma and eosinophilic bronchitis. J Allergy Clin Immunol. 2004;114:1106–1109.
   PubMed Web of Science ®Google Scholar
• Prieto J, Lensmar C, Roquet A, et al. Increased interleukin-13 mRNA expression in bronchoalveolar lavage cells of atopic patients with mild asthma after repeated low-dose allergen provocations. Respir Med. 2000;94:806–814.
   PubMed Web of Science ®Google Scholar
• Saha SK, Berry MA, Parker D, et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol. 2008;121:685–691.
   PubMed Web of Science ®Google Scholar
• Schmid-Grendelmeier P, Altznauer F, Fischer B, et al. Eosinophils express functional IL13 in eosinophilic inflammatory diseases. J Immunol. 2002 15;169:1021–1027.
   PubMed Web of Science ®Google Scholar
• Park SW, Jangm HK, An MH, et al. Interleukin-13 and interleukin-5 in induced sputum of eosinophilic bronchitis: comparison with asthma. Chest. 2005;128:1921–1927.
   PubMed Web of Science ®Google Scholar
• Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet. 2015 12;386:1086–1096.
   PubMed Web of Science ®Google Scholar
• Truyen E, Coteur L, Dilissen E, et al. Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients. Thorax. 2006;61:202–208.
   PubMed Web of Science ®Google Scholar
• Leigh R, Ellis R, Wattie J, et al. Is interleukin-13 critical in maintaining airway hyperresponsiveness in allergen-challenged mice? Am J Respir Crit Care Med. 2004 15;170:851–856.
   PubMed Web of Science ®Google Scholar
• Van Rijt L, von Richthofen H, van Ree R. Type 2 innate lymphoid cells: at the cross-roads in allergic asthma. Semin Immunopathol. 2016;38:483–496.
   PubMed Web of Science ®Google Scholar
• Belperio JA, Dy M, Burdick MD, et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2002;27:419–427.
   PubMed Web of Science ®Google Scholar
• Yang G, Li L, Volk A, et al. Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice. J Pharmacol Exp Ther. 2005;313:8–15.
   PubMed Web of Science ®Google Scholar
• Bergeron C, Tulic MK, Hamid Q. Airway remodelling in asthma: from benchside to clinical practice. Can Respir J. 2010;17:e85–e93.
   PubMed Web of Science ®Google Scholar
• Tsilogianni Z, Hillas G, Bakakos P, et al. Sputum interleukin-13 as a biomarker for the evaluation of asthma control. Clin Exp Allergy. 2016;46:923–931.
   PubMed Web of Science ®Google Scholar
• Naseer T, Minshall EM, Leung DY, et al. Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy. Am J RespirCrit Care Med. 1997;155:845–851.
   PubMed Web of Science ®Google Scholar
• Munitz A, Brandt EB, Mingler M, et al. Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha1 and the type II IL-4 receptor in asthma pathogenesis. Proc Natl AcadSci U S A. 2008 20;105:7240–7245.
   PubMed Web of Science ®Google Scholar
• Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy ClinImmunol. 2006;117:522–543.
   PubMed Web of Science ®Google Scholar
• Hamid QA, Wenzel SE, Hauk PJ, et al. Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma. Am J RespirCrit Care Med. 1999;159:1600–1604.
   PubMed Web of Science ®Google Scholar
• Maneechotesuwan K, Yao X, Ito K, et al. Suppression of GATA-3 nuclear import and phosphorylation: a novel mechanism of corticosteroid action in allergic disease. PLoS Med. 2009 12;6:e1000076.
   PubMed Web of Science ®Google Scholar
• Kelly A, Bowen H, Jee YK, et al. The glucocorticoid receptor beta isoform can mediate transcriptional repression by recruiting histone deacetylases. J Allergy ClinImmunol. 2008;121:203–208.e1.
   PubMed Web of Science ®Google Scholar
• Spahn JD, Szefler SJ, Surs W, et al. A novel action of IL-13: induction of diminished monocyte glucocorticoid receptor-binding affinity. J Immunol. 1996 15;157:2654–2659.
   PubMed Web of Science ®Google Scholar
• Kraft M, Hamid Q, Chrousos GP, et al. Decreased steroid responsiveness at night in nocturnal asthma. Is the macrophage responsible? Am J RespirCrit Care Med. 2001;163:1219–1225.
   PubMed Web of Science ®Google Scholar
• Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Med. 2013;19:977–979.
   PubMed Web of Science ®Google Scholar
• Finotto S, Hausding M, Doganci A, et al. Asthmatic changes in mice lacking T-bet are mediated by IL-13. Int Immunol. 2005;17:993–1007.
   PubMed Web of Science ®Google Scholar
• Gour N, Wills-Karp M. IL-4 and IL-13 signaling in allergic airway disease. Cytokine. 2015;75:68–78.
   PubMed Web of Science ®Google Scholar
• Luo J, Liu D, Liu CT. The efficacy and safety of antiinterleukin 13, a monoclonal antibody, in adult patients with asthma: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95:e2556.
   PubMed Web of Science ®Google Scholar
• Piper E, Brightling C, Niven R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41:330–338.
   PubMed Web of Science ®Google Scholar
• Brightling CE, Chanez P, Leigh R, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebocontrolled, phase 2b trial. Lancet Respir Med. 2015;3:692–701.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007 20;370:1422–1431.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015;70:748–756.
   PubMed Web of Science ®Google Scholar
• Thomson NC, Patel M, Smith AD. Lebrikizumab in the personalized management of asthma. Biologics. 2012;6:329–335.
   PubMedGoogle Scholar
• Tiwari A, Kasaian M, Heatherington AC, et al. A mechanistic PK/PD model for two anti-IL13 antibodies explains the difference in total IL-13 accumulation observed in clinical studies. MAbs. 2016;8:983–990.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 27;368:2455–2466.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Castro M, Corren J,,, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016 2;388:31–44.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4:781–796.
   PubMed Web of Science ®Google Scholar
• Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011 22;365:1088–1098.
   PubMed Web of Science ®Google Scholar
• Nair P, O’Byrne PM. Measuring eosinophils to make treatment decisions in asthma. Chest. 2016;150:485–487.
   PubMed Web of Science ®Google Scholar
• Simpson JL, Scott R, Boyle MJ, et al. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006;11:54–61.
   PubMed Web of Science ®Google Scholar
• Schleich FN, Seidel L, Sele J, et al. Exhaled nitric oxide thresholds associated with a sputum eosinophil count >/=3% in a cohort of unselected patients with asthma. Thorax. 2010;65:1039–1044.
   PubMed Web of Science ®Google Scholar
• Noonan M, Korenblat P, Mosesova S, et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol. 2013;132:567–74.e12.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388–395.
   PubMed Web of Science ®Google Scholar
• Corren J. Anti-interleukin-13 antibody therapy for asthma: one step closer. Eur Respir J. 2013;41:255–256.
   PubMed Web of Science ®Google Scholar
• Maselli DJ, Keyt H, Rogers L. Profile of lebrikizumab and its potential in the treatment of asthma. J Asthma Allergy. 2015 10;8:87–92.
   PubMed Web of Science ®Google Scholar
• Jia G, Erickson RW, Choy DF, et al. Bronchoscopic Exploratory Research Study of Biomarkers in Corticosteroid-refractory Asthma (BOBCAT) Study Group. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012;130:647–654.
   PubMed Web of Science ®Google Scholar
• Peters MC, Nguyen ML, Dunican EM. Biomarkers of airway type-2 inflammation and integrating complex phenotypes to endotypes in asthma. Curr Allergy Asthma Rep. 2016;16:71.
   PubMed Web of Science ®Google Scholar
• Wagener AH, de Nijs SB, Lutter R, et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70:115–120.
   PubMed Web of Science ®Google Scholar
• Konstantellou E, Loukides S, Ntontsi P, et al. The association between serum periostin and a type 2 helper airway composite index in optimally treated asthmatics. J Allergy Clin Immunol Pract. 2017;5:1129–1131.
   PubMed Web of Science ®Google Scholar
• Silkoff PE, Flavin S, Gordon R, et al. Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations: a randomized controlled study. J Allergy Clin Immunol. 2017. pii: S0091-6749(17)31107-7.
   Web of Science ®Google Scholar
• Nagasaki T, Matsumoto H, Kanemitsu Y, et al. Using exhaled nitric oxide and serum periostin as a composite marker to identify severe/steroid-insensitive asthma. Am J Respir Crit Care Med. 2014 15;190:1449–1452.
   PubMed Web of Science ®Google Scholar
• Shirley M. Dupilumab: first global approval. Drugs. 2017;77:1115–1121.
   PubMed Web of Science ®Google Scholar